Science 37, a Los Angeles, CA-based based technology-enabled clinical research company, completed a $6.5m Series A financing.
The round was co-led by Lux Capital and dRx Capital.
The company intends to use the funds to accelerate development and rollout of its new operating model.
Led by Noah Craft, MD, PhD, co-founder and CEO, Science 37 has pioonered a new metasite™ operating model which delivers end-to-end clinical trial services under a single contract by leveraging partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups and other technology companies to maximize efficiency.
The company’s cloud-based patient-centric mobile research platform, the Network Oriented Research Assistant (NORA®), utilizes telemedicine and coordinates mobile workforces to overcome geographic barriers and allow them to can take part in trials, including underserved and minority populations and enhance engagement for better collection of real world data, improved medication adherence and safety monitoring, and finally, an increased likelihood of trial success.
Science 37 is already creating a technology-enabled metasite™ in a Phase III FDA-registered trial with a major pharmaceutical company.